Abacavir-Lamivudine-Zidovudine (Trizivir)

All References

• Berenguer J, Pérez-Elías MJ, Bellón JM, et al. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr. 2006;41:154-9.
  [PubMed Abstract]
• Bonjoch A, Paredes R, Galvez J, et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr. 2005;39:313-6.
  [PubMed Abstract]
• Cahn P, Vibhagool A, Schechter M, et al. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Curr Med Res Opin. 2004;20:1115-23.
  [PubMed Abstract]
• Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS. 2001;15:1517-26.
  [PubMed Abstract]
• Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 pregnant women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-94.
  [PubMed Abstract]
• Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cochrane Database Syst Rev. 2013;:CD008270.
  [PubMed Abstract]
• Dorjee K, Baxi SM, Reingold AL, Hubbard A. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017;17:708.
  [PubMed Abstract]
• Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018;52:541-53.
  [PubMed Abstract]
• Fischl MA, Burnside AE Jr, Farthing CE, et al. Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. Pharmacotherapy. 2003;23:1432-40.
  [PubMed Abstract]
• Gulick RM, Lalama CM, Ribaudo HJ, et al. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007;21:813-23.
  [PubMed Abstract]
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296:769-81.
  [PubMed Abstract]
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61.
  [PubMed Abstract]
• Henry K, Wallace RJ, Bellman PC, et al. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. J Infect Dis. 2001;183:571-8.
  [PubMed Abstract]
• John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
  [PubMed Abstract]
• Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med. 2003;4:79-86.
  [PubMed Abstract]
• Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511-8.
  [PubMed Abstract]
• Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85-98.
  [PubMed Abstract]
• Kumar PN, Salvato P, Lamarca A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther. 2009;6:3.
  [PubMed Abstract]
• Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007;195:1169-76.
  [PubMed Abstract]
• Lafeuillade A, Clumeck N, Mallolas J, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study. HIV Clin Trials. 2003;4:37-43.
  [PubMed Abstract]
• Langebeek N, Sprenger HG, Gisolf EH, et al. A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial. HIV Med. 2014;15:286-90.
  [PubMed Abstract]
• Mallolas J, Pich J, Peñaranda M, et al. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. AIDS. 2008;22:377-84.
  [PubMed Abstract]
• Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39:257-64.
  [PubMed Abstract]
• Matheron S, Descamps D, Boué F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther. 2003;8:163-71.
  [PubMed Abstract]
• Neely M, Rutstein R, Del Bianco G, et al. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. Pediatr Infect Dis J. 2013;32:e370-6.
  [PubMed Abstract]
• Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis. 2002;185:1251-60.
  [PubMed Abstract]
• Palma P, Romiti ML, Cancrini C, et al. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. AIDS. 2007;21:2465-72.
  [PubMed Abstract]
• Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010;201:662-71.
  [PubMed Abstract]
• Pérez-Elías MJ, Moreno A, Moreno S, et al. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin Trials. 2005;6:312-9.
  [PubMed Abstract]
• Ross L, Elion R, Lanier R, et al. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). AIDS Res Hum Retroviruses. 2009;25:665-72.
  [PubMed Abstract]
• Sáez-Llorens X, Nelson RP Jr, Emmanuel P, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics. 2001;107:E4.
  [PubMed Abstract]
• Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547-54.
  [PubMed Abstract]
• Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database Syst Rev. 2013;:CD005481.
  [PubMed Abstract]
• Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44:540-50.
  [PubMed Abstract]
• Sprenger HG, Langebeek N, Mulder PG, et al. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study. HIV Med. 2015;16:122-31.
  [PubMed Abstract]
• Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA. 2001;285:1155-63.
  [PubMed Abstract]
• Stürmer M, Dauer B, Moesch M, et al. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther. 2007;12:25-30.
  [PubMed Abstract]
• Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin. 2004;20:1103-14.
  [PubMed Abstract]
• Wolbers M, Opravil M, von Wyl V, et al. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS. 2007;21:2201-7.
  [PubMed Abstract]